Sign In
Buy IBB
$167.50
+3.23 (+1.97%)
At Close: Jun 03, 2026
iShares Biotechnology ETF: The M&A Wave Behind The Suddenly Booming Biotech Sector
09:44am, Monday, 17'th Nov 2025
The biotech sector, represented by the iShares Biotechnology ETF, has experienced a notable rally in recent months. The key driver of the 40% over the past six months has been a notable uptick in M&A
If M&A continues at this pace you want to be long Biotech into next year, says Mizuho's Jared Holz
06:17pm, Friday, 14'th Nov 2025
Jared Holz, Mizuho, joins 'Fast Money' to talk the uptick in biotech and pharma M&A, what it is signaling, and how to play it.
'Fast Money' traders talk how to play biopharma space
06:56pm, Tuesday, 11'th Nov 2025
The 'Fast Money' traders talk how to play biopharma space.
Why the Tide in Biotech May Finally Be Turning and What iShares Biotechnology ETF (IBB) Signals
01:50pm, Monday, 03'rd Nov 2025
Acquired 77,000 shares, valued at $11.1 million Transaction represents 8.7% of 13F reportable AUM Post-trade position: 77,000 shares valued at $11.1 million IBB is now the fund's 2nd-largest holding,
Biotech ETFs Hovering Around a 52-Week: Here's Why
10:01am, Thursday, 30'th Oct 2025
Biotech-based exchange-traded fund (ETF) iShares Biotechnology ETF IBB has rallied 26.1% over the past six months (as of Oct. 27, 2025), outperforming SPDR S&P 500 ETF Trust SPY (up 24.4%). Year t
Cwm LLC Sells 1,371 Shares of iShares Biotechnology ETF $IBB
05:00am, Thursday, 23'rd Oct 2025
Cwm LLC decreased its holdings in shares of iShares Biotechnology ETF (NASDAQ: IBB) by 17.4% in the undefined quarter, according to its most recent Form 13F filing with the SEC. The firm owned 6,521 s
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
07:21am, Monday, 20'th Oct 2025
A smart beta exchange traded fund, the iShares Biotechnology ETF (IBB) debuted on 02/05/2001, and offers broad exposure to the Health Care ETFs category of the market.
Biotech ETFs Bounce Back in 2025: Here's Why
07:01am, Monday, 20'th Oct 2025
Biotech ETFs rally. IBB, ARKG, SBIO, BBC, CANC and BBP soar as Fed rate cut optimism, FDA approvals, deals and cheaper valuations drive the space in 2025.
Trade Tracker: Jason Snipe buys the IBB
01:30pm, Friday, 17'th Oct 2025
Jason Snipe, Founder and CIO of Odyssey Capital Advisors joins CNBC's “Halftime Report” to detail his latest purchase of the IBB.
Should You Invest in the iShares Biotechnology ETF (IBB)?
07:21am, Monday, 13'th Oct 2025
Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the iShares Biotechnology ETF (IBB), a passively managed exchange traded fund launched on Febru
Destiny Wealth Sells $8.1 Million in IBB Shares — Here's Why Biotech Stocks Are Lagging
02:23pm, Tuesday, 07'th Oct 2025
Destiny Wealth Partners reported in an SEC filing on Monday that it sold 59,354 shares of the iShares Biotechnology ETF (IBB) in the third quarter—an estimated $8.1 million transaction based on aver
My Top 5 Biotech Stocks Big Pharma Could Buy Next
01:29pm, Monday, 06'th Oct 2025
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of
Trump's Biotech Playbook Ignites $350 Billion Investment Blitz
10:41am, Tuesday, 09'th Sep 2025
Biotech is back – and it's playing for keeps. President Donald Trump's second-term policies have unleashed a staggering ~$350 billion surge in U.S.-based pharmaceutical and biotech investments, from
Real assets in biotech serving big markets the Street is finally noticing, says Mizuho's Jared Holz
03:32pm, Wednesday, 03'rd Sep 2025
Jared Holz, Mizuho healthcare strategist, joins 'Power Lunch' to discuss the change in sentiment in the healthcare sector, the differences in the biotech ETFs and much more.
BBH Vs. IBB: How To Prepare For The Next Biotech Growth Cycle With BBH
08:03am, Monday, 01'st Sep 2025
Biotech is entering a new growth cycle driven by AI and CRISPR innovation, but current ETF valuations are high and volatility is elevated. BBH offers a concentrated portfolio of leading innovators wit
